20 completed. 20 Phase 1.
By phase and status
Follow Solid Cancers: new trials by email Literature Review of Solid Cancers trials Research Report on Solid Cancers
Trials (filtered) newest first · largest first
All 20 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells - Colorectal Cancer, Solid Cancers | Phase 1 | Completed | 58 | 2022-05-25 | 2026-07-15 |
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Atezolizumab, Emactuzumab - Solid Cancers | Phase 1 | Completed | 221 | 2015-01-19 | 2020-08-27 |
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors Atezolizumab, Bevacizumab, Interferon alfa-2b - Solid Cancers | Phase 1 | Completed | 158 | 2014-08-18 | 2020-05-12 |
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Grape Seed Extract, Vitamin D - Solid Cancers | Phase 1 | Completed | 22 | 2013-03-01 | 2018-05-18 |
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors GDC-0980, bevacizumab, carboplatin - Solid Cancers | Phase 1 | Completed | 75 | 2011-09-01 | 2016-11-02 |
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors GDC-0980, bevacizumab, capecitabine - Solid Cancers | Phase 1 | Completed | 41 | 2011-07-01 | 2016-11-02 |
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol - Solid Cancers | Phase 1 | Completed | 52 | 2010-11-01 | 2015-06-29 |
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma GDC-0917 - Solid Cancers | Phase 1 | Completed | 42 | 2010-10-01 | 2016-11-02 |
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors MINT1526A, bevacizumab - Solid Cancers | Phase 1 | Completed | 54 | 2010-06-01 | 2016-11-02 |
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors GDC-0623 - Solid Cancers | Phase 1 | Completed | 61 | 2010-04-01 | 2016-11-02 |
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors GDC-0068 - Solid Cancers | Phase 1 | Completed | 52 | 2010-03-01 | 2016-07-04 |
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors MEGF0444A, bevacizumab, paclitaxel - Solid Cancers | Phase 1 | Completed | 64 | 2010-02-01 | 2016-11-02 |
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists GDC-0449 - Solid Cancers | Phase 1 | Completed | 67 | 2009-09-01 | 2017-07-11 |
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors bevacizumab, MNRP1685A, paclitaxel - Solid Cancers | Phase 1 | Completed | 24 | 2009-08-01 | 2017-05-17 |
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer carboplatin, docetaxel, trastuzumab - Solid Cancers | Phase 1 | Completed | 59 | 2009-07-01 | 2015-12-10 |
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors MEGF0444A - Solid Cancers | Phase 1 | Completed | 30 | 2009-05-22 | 2022-12-12 |
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors MNRP1685A - Solid Cancers | Phase 1 | Completed | 35 | 2008-09-01 | 2011-04-20 |
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable GDC-0941 - Solid Cancers | Phase 1 | Completed | 108 | 2007-10-01 | 2016-11-02 |
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors bevacizumab, MetMAb - Solid Cancers | Phase 1 | Completed | 44 | 2007-08-01 | 2017-05-19 |
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors SF1126 - Advanced or Metastatic Solid Tumors, Cancer | Phase 1 | Completed | 44 | 2007-04-01 | 2013-06-13 |
Narrower conditions
Neoplasms (2) · Carcinoma, Basal Cell (1) · Colorectal Neoplasms (1) · Stomach Neoplasms (1)
Broader conditions
Neoplasms (2) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Basal Cell (1) · Neoplasms, Glandular and Epithelial (1) · Rectal Diseases (1) · Stomach Diseases (1)
Interventions
Bevacizumab (7) · Paclitaxel (3) · 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (2) · Carboplatin (2) · HhAntag691 (2) · atezolizumab (2) · parsatuzumab (2) · vesencumab (2) · 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine (1) · Capecitabine (1) · Cisplatin (1) · Docetaxel (1) · GDC-0623 (1) · Grape Seed Extract (1) · Interferon alpha-2 (1)
Sponsors
Genentech, Inc. (15) · Hoffmann-La Roche (2) · Medical University of South Carolina (1) · Semafore Pharmaceuticals (1) · Weijia Fang, MD (1)
Countries
United States (13) · Spain (4) · Belgium (1) · China (1) · France (1) · Netherlands (1)
Top investigators
Rainer Brachmann, M.D. (2) · Chia Portera, M.D., Ph.D. (1) · Dawn Colburn, Pharm.D. (1) · Donald L Durden, MD, PhD (1) · Harald Weber, M.D. (1) · Ina Rhee, M.D. (1) · Jennifer Low, M.D. (1) · Jerry Hsu, M.D. (1) · Louie Naumovski, M.D., Ph.D. (1) · Premal Patel, M.D. (1) · Premal Patel, M.D., Ph.D. (1) · Weijia Fang, M.D (1)
Results publications
PMID 22921184, PMID 25009010, PMID 27872130, PMID 28250200, PMID 34471960, PMID 35577503, PMID 39734708, PMID 41760800
NIH funding
2014 (2), 2009 (1)